Twist Bioscience Corp. Hits New 52-Week High at $145.67

Twist Bioscience Corp. has reached a significant milestone by hitting a new 52-week high of USD 145.67 on August 21, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 191.12%, significantly outpacing the S&P 500's growth of 20.47%. As a small-cap player in the Pharmaceuticals & Biotechnology industry, Twist Bioscience has garnered attention for its innovative approaches and strategic positioning within the market. The company's market capitalization stands at USD 2,730 million, reflecting its growing influence in the sector. Despite being loss-making, as indicated by its P/E ratio, the firm continues to navigate the competitive landscape with a debt-to-equity ratio of -0.41 and a return on equity of -16.79%. Investors may note that the stock's 52-week low was recorded at USD 23.50, highlighting the substantial recovery and growth trajectory the company has experienced. With no dividend yield currently offered, Twist Bioscience remains focused on its core operations and market expansion efforts.